Hence, one might seek to enhance tumor suppressor CDC73’s stability in cancer cells by maintaining its phosphorylated state, thus inhibiting its ubiquitination and degradation mediated by UBR5, as a potential therapeutic strategy for breast cancer patients with low CDC73 levels. This evidence concerns the gene UBR5 and neoplasm.